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Deep brain stimulation in Tourette’s
syndrome
Avram Fraint* and Gian Pal
Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA
Objective: Tourette’s syndrome (TS) is defined by 1 year of persistent motor and vocal
tics. Often, the tics are refractory to conventional pharmacologic and psychobehavioral
interventions. In these patients, deep brain stimulation (DBS) may be an appropriate
intervention. This paper reviews different DBS targets in TS, discusses existing evidence
on the efficacy of DBS in TS, highlights adverse effects of the procedure, discusses
indications and patient selection as well as future directions for DBS in TS.
Methods: A literature review searching PubMed database entries between 2000 and
2015. Search terms included “DBS in Tourette Syndrome”, “Deep brain stimulation in
Tourette syndrome,” and “Surgical management of Tourette Syndrome.”
Results: Though there are no universally accepted guidelines defining ideal DBS can-
didates for TS, age, tic severity, and treatment refractoriness are important factors to
consider in patient selection. A variety of targets exist for DBS in TS, but thalamic targets
andGPi are themost widely studied. Psychiatric side effects that are target specific should
be monitored closely and it is possible that these adverse effects may be resolved with
programing. Small randomized controlled trials support the efficacy of DBS in TS.
Conclusion: DBS for TS is safe and feasible, but large multi-center clinical trials are
needed to determine the ideal target and optimal location within a particular target.
Keywords: deep brain stimulation, DBS, Tourette’s syndrome, tics, TS
Introduction
Tourette’s syndrome (TS) is defined by 1 year of persistent, waxing and waning motor, and vocal
tics. Up to 90% of patients with TS have co-morbid psychiatric conditions including Obsessive-
Compulsive Disorder (OCD) and Attention Deficit Hyperactivity Disorder (ADHD). Tics usually
occur at a mean age of 5–7 years and usually remit by early adulthood (1). Patients with TS
usually respondwell to pharmacologic treatments, including alpha2 adrenergics, typical and atypical
neuroleptics, and ADHDmedications. Psychobehavioral therapies, including habit reversal therapy
(HRT), are also integral to TS treatment. Despite the availability of numerous treatments, some cases
remain refractory to pharmacologic and behavioral interventions.
Deep brain stimulation (DBS) may be an option for medically intractable and severe cases of TS.
Very severe tics and psychiatric co-morbidities can cause social impairment, isolation, and pain, and
in these patients DBSmay be appropriate. Though DBS has shown clear efficacy in other movement
disorders including Parkinson’s disease (PD), dystonia, and essential tremor (ET), the benefit of DBS
in TS is still unclear for a variety of reasons. First, no consensus has been reached concerning which
TS patients are appropriate candidates for DBS. Second, the pathophysiology of the disease remains
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to be elucidated and hence the optimal target has yet to be iden-
tified. Further, many of the studies of DBS in TS are only case
reports and not randomized controlled trials (RCTs). Lastly, the
population of TS patients is not homogenous, and since waxing
and waning symptoms are part of the disease itself, it is difficult in
these cases to truly assess the long-term benefit of DBS.
We aim to shed light on these issues by highlighting the most
researched targets for DBS in TS, reviewing indications and
patient selection, and describing adverse effects through the lens
of the most recent and highest quality level of evidence available
to date.
Methods
We reviewed PubMed entries between 2000 and 2015. The fol-
lowing search terms were used: “DBS in Tourette Syndrome,”
“Deep brain stimulation in Tourette syndrome,” and “Surgical
management of Tourette Syndrome.” The search engine generated
201 publications. Epidemiologic studies, case series, and RCTs
were included and reviewed. All journal articles reviewed were
written in English.
Current Indications and Patient Selection
There are no universally accepted guidelines defining ideal DBS
candidates for TS. Indeed, many different groups have proposed
slightly different guidelines over time, but no single guideline has
gained widespread acceptance (2, 3). However, common themes
can be gleaned from the available guidelines, which are summa-
rized in Table 1. First, the patient must be diagnosed with TS
according to the criteria specified in the DSM-5 and by a clinician
who has experience with the diagnosis of TS and tic disorders.
Tics should be the main symptom and they must cause significant
impairment in quality of life, particularly impacting relation-
ships, home environment and/or school/work. The tics should be
treatment resistant and co-morbid psychiatric diagnoses must be
adequately treated to maximize follow up and compliance. The
patient should not suffer from behaviors that will lead to damage
of the electrodes or stimulator, including obsessive picking at the
insertion site so as to reduce the risk of infection (4). Ultimately,
three main factors influence patient selection for DBS in TS – age,
tic severity, and treatment refractoriness.
It is generally accepted that DBS should be reserved for adults,
as most cases of TS remit spontaneously during early adulthood
(5). Typically, guidelines have recommended offering the surgery
only to individuals who are at least 18 years of age, but others
recommend a minimum cutoff of 25 (6). The youngest reported
patient who has undergone DBS for TS is 16, however, this patient
was unique in that he was mentally disabled and his disease was
so severe and refractory to typical treatments that he became
depressed, isolated, and suicidal (7). Most recently, Schrock et al.
indicated that age alone is not a strict exclusion criterion for DBS
in TS (2015), however, that for patients under 18, a local ethics
committee should be consulted.
There is agreement that only patients with “severe” TS should
be considered candidates for DBS (4, 8). Scales such as the Yale
Global Tic Severity Scale (YGTSS) are generally used to quantify
disease severity (9). Most guidelines suggest that patients should
have a score 35/50 on the YGTSS, which is generally accepted
as “severe.” However, others argue that an assessment of social
impairment is required to truly assess disease severity, and this is
a limitation of using the YGTSS alone (1). Further, premonitory
sensations, somatic aspects of the disease and self-perception of
severity may also be important factors to consider when assessing
severity, rather than relying on strict cut-off scores (1). Schrock
et al. (3) propose that the tics should cause functional impairment,
but agree that YGTSS above 35/50 defines “severe” disease.
It is accepted that DBS candidates’ disease must be “resistant”
or “refractory” to pharmacologic and behavioral treatments (4),
but the definition of these terms is variable. According to the
TSA guidelines (10), TS patients should have failed treatment
with or had severe side effects from alpha-adrenergic agonists,
typical and atypical antipsychotics and a benzodiazepine. The
Dutch/Flemish guidelines (11) suggest that at least three medi-
cations (including typical and atypical antipsychotics) should be
tried at adequate doses for 12weeks while other groups have
suggested aminimum treatment period of 6months (1) to be con-
sidered medication-refractory. The European Society for Study of
Tourette Syndrome (ESSTS) guidelines suggest that the tics must
be present for at least 5 years and must be considered “severe”
for 1 year before DBS is performed (4). Schrock et al. (3) require
failed treatment trials of alpha-adrenergic agonists, dopamine
antagonists (both typical and atypical), and a drug from a third
medication class.
TABLE 1 | Proposed inclusion and exclusion criteria for DBS use in TS.
Inclusion criteria Exclusion criteria
At least 18 years old. Younger patients would require approval from local ethics committee Under 18 years old without approval from local ethics committee
DSM-V diagnosis of TS Active suicidal or homicidal ideation
Severe tics, as defined by YGTSS >35/50 Ongoing or recent substance abuse
Tics are the main source of disability Structural lesions on MRI
Tics are refractory to three classes of conservative pharmacologic therapy and CBT has
been offered
Co-morbid medical or psychiatric conditions that increase the risk of a
failed procedure or interference with post-operative management
Psychiatric co-morbidities are being treated and are stable for at least 6months Malingering, factitious, psychogenictics
Stable environment with reliable and stable social supports
Demonstrated adherence to recommended therapies
Neuropsychological profile indicating the patient can tolerate demands of surgery and
post-operative follow up schedule
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Most guidelines also recommend trial and failure of behavioral
therapy before consideringDBS. According to the TSA guidelines,
patients must have failed 12 successive sessions of behavioral ther-
apy, including habit reversal and exposure type therapies. Schrock
et al. indicate that an expert clinician should be comfortable ruling
out malingering, factitious disorder and psychogenic tics before
proceedingwith surgery and selected patients should be capable of
adhering to proposed follow up guidelines. Schrock et al. propose
that a trial of CBT should be offered. They add that adequate social
support should be evident with a caregiver who is available to
accompany the patient to frequent follow-up visits (2015).
DBS Targets for TS
At the present time, no definitive surgical target has been
agreed upon. Due to wide inter-patient variability and co-
morbidities, multiple targets have been used. A total of eight
suitable targets have been identified: two in the thalamus [the cen-
tromedian parafascicular complex (CM–Pf) and centromedian
nucleus-substantia periventricularis-nucleus ventro-oralis inter-
nus (CM–Spv–Voi)], two in the globus pallidus internus (the
postero-ventrolateral region and the antero-medial region), the
nucleus accumbens (NA), the anterior limb of the internal capsule
(AIC), the subthalamic nucleus (STN) and the globus pallidus
externus (GPe). Combinations of these different targets have been
tried as well (12–14) (Figure 1). Despite the variety and combina-
tions tried, the thalamus and globus pallidus internus are themost
widely studied and targeted areas for TS.
Thalamic Targets
The CM–Pf region of the thalamus is by far the most widely stud-
ied target, as cells in its anterior region are thought to influence tic
generation (1). In 1970, Hassler and Dieckmann described three
patients who underwent thalamotomy of the CM–Pf for treatment
of TS (15). One patient reported improvement in echolalia within
hours after surgery and complete remission of premonitory urges
toward tics as well as coprolalia when followed up 1 year later.
The second patient reported complete remission of coprolalia
soon after surgery, and the third reported a reduction in tics and
obsessive crying by 1 year after surgery. However, it was not until
1999 that Visser-Vandewalle et al. used thalamic DBS to treat
severe and refractory TS in a 42-year-old man. They reported
substantial improvement in frequency of motor tics at a 4month
post-operative time point (16). Additional larger series have
also reported significant improvement with thalamic targeting.
Servello et al. (12) examined the effects of CM–Pf stimulation in
34 subjects. The average YGTSS score improved from 75.5 12.6
to 40.0 14.1 (p< 0.001) over a follow-up period of 3months
to 2 years. Similarly, Porta et al. (1) described a series of 15
patients who experienced an improvement of mean YGTSS
from 76.5 to 36.6 at 2-year follow up. Symptoms of depression,
anxiety, OCD, obsessive-compulsive behaviors (OCBs), and
subjective perception of social impairment decreased as well.
Specifically, Yale-Brown Obsessive Compulsive Scale (YBOCS)
scores improved from 20.9 to 14.4 (p= 0.009), Beck Depression
Inventory (BDI) scores improved from 30.7 to 22.7 (p= 0.001)
and State-Trait Anxiety Inventory (STAI) scores improved from
44.2 to 29.5 (p= 0.001).
Thalamus
centromedian
parafascicular complex 
(CM-Pf) 
centromedian nucleus-
substan!a 
periventricularis-
nucleus ventro-oralis
internus (CM-Spv-Voi)
Globus Pallidus 
Internus (GPi)
postero-ventrolateral 
region 
antero-medial region
Addi!onal 
Targets
nucleus accumbens
(NA)
anterior limb of 
internal capsule (AIC)
subthalamic nucleus 
(STN)
globus pallidus
externus (GPe)
FIGURE 1 | DBS targets in Tourette’s syndrome [Servello et al. (12); Servello et al. (13); Shields et al. (14)].
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Another region of the thalamus, the CM–Spv–Voi was shown
to be effective in three adults for medically intractable TS (17).
However, no systematic scale was used to evaluate these patients,
but rather improvement was based on number of tics seen during
a specified time period at a particular stimulation level.
The efficacy of thalamic DBS for TS has been attributed to
modulation of excessive thalamocortical drive (18). It has been
posited that cortical excitation of the striatum and STN results
in inhibitory projections to the thalamus and midbrain, thus
modulating motor patterns of the cerebral cortex and brainstem
(18). Further, abnormal inhibition of the GPi and substantia
nigra pars reticulata (SNpr) by inappropriate activation of striatal
neurons may lead to increased thalamocortical drive, resulting in
unwanted motor patterns and execution of tics (18). There is also
evidence for thalamic DBS resulting in a reduction of increased
dopaminergic transmission in the thalamus (19, 20).
Globus pallidus internus
Globus pallidus internus DBS has been explored as another key
target for TS DBS. Cavanna et al. (6) cite four key reasons for
GPi as their preferred target for TS: (1) GPi plays a central role
in the cortico-striato-thalamo-cortical circuitry involved in TS
pathophysiology; (2)GPi has been shown to bemore effective than
thalamic DBS in one small series (21); (3) lack of side effects with
GPi stimulation; (4) GPi is readily visible on MRI for more facile
implantation.
In a small pilot study, Welter et al. (21) found bilateral GPi
stimulation produced a more favorable outcome in tic severity
(78% reduction) compared with thalamic CM–Pfc stimulation
(45% reduction). Larger series also support the efficacy of GPi
stimulation for TS. Cannon et al. (22) reported on eleven patients
that had GPi DBS implantation for TS and these subjects had a
mean reduction of 50% in the YGTSS at 3months of follow up.
Similarly, Zhang et al. (23) reported outcomes in 13 subjects with
treatment refractory TS who underwent GPi DBS. These subjects
had a mean reduction in YGTSS of 52.1% (range 4.3–83.6%) over
a mean follow-up period of 41.9months (range 13–80months).
Also, the Gilles de la Tourette Syndrome-Quality of Life Scale
score improved by a mean of 45.7% (range 11.0–77.2%).
Though GPi is a promising target, there is a debate regarding
the optimal location for electrode placement in GPi. Some groups
have suggested the posteroventral (sensorimotor) region (24–27),
while others have targeted the antero-medial (limbic) portion of
GPi (21, 28, 29). Large multi-center trials are needed to determine
the efficacy of DBS in GPi, as well as the optimal location within
GPi for stimulation.
Other Targets
In addition to the thalamus and GPi, other DBS targets have been
explored as well. Sturm et al. (30) reported effectiveness of DBS of
the NA in four patients with severe OCD and anxiety. Welter et al.
(21) reported a significant and greater reduction in YGTSS with
stimulation of the NA compared to stimulation of CM/Pf of the
thalamus in three patientswith severeTS.Kuhn et al. (31) reported
that DBS of the NA resolved tics and coprolalia in one 26-year-old
man with severe TS. Flaherty et al. (32) reported one woman who
underwent DBS of the AIC (with an electrode terminating in the
NA) and experienced significant reduction in tic frequency and
severity at 18months. Though these different targets have been
explored, they are only used in small case series. The focus remains
on the thalamus and GPi as the most promising potential targets.
Randomized Controlled Trials Supporting
the Efficacy of DBS for TS
At the present time, five randomized double-blind control trials
have evaluated the utility ofDBS for TS.Houeto et al. (29) reported
a prospective, double-blind study of one patient who underwent
bilateral CM–Pf thalamic and bilateral antero-medial GPi lead
implantation. Tic severity was assessed 1month before implan-
tation and then at various intervals after surgery in a double-
blinded, randomized protocol in five phases: no stimulation, bilat-
eral thalamic stimulation, bilateral GPi stimulation, a sham trial
where the stimulators were turned off, and combined thalamic
and GPi stimulation. After bilateral thalamic stimulation, the
patient had a 65% reduction in the YGTSS and a 77% improve-
ment on the Rush Video-Based Tic Rating Scale (RVBTS) after
2months of stimulation. The patient also reported fewer self-
injurious behaviors. Bilateral GPi stimulation produced a 65%
reduction in the YGTSS and a 67% improvement in the RVBTS
after 2months of stimulation. GPi stimulation also produced a
reduction in self-injurious behaviors, thoughmood and impulsiv-
ity were worse compared to bilateral thalamic stimulation. Inter-
estingly, 2months of combined bilateral thalamic and GPi stimu-
lation produced complete cessation of self-injurious behavior and
a 70% reduction in YGTSS, and these improvements persisted at
2 years after the procedure.
Maciunas et al. (33) reported five patients who underwent
stimulation of bilateral thalamic CM–Pf in a randomized, double-
blinded trial. The randomization period began 1month after
implantation. The patients spent 1week in each of the following
states: both stimulators off, left on and right off, right on and
left off, and both on. Blinded subjective and objective results
were assessed at the end of each week. There was a statistically
significant reduction of 4.2 points (a 53% reduction in tics) in the
modified Rush Video-Based Tic Rating Scale (mRVBTS) score in
the bilateral stimulation state. There was improvement in motor
and vocal tics as well as in the YGTSS and TS Symptom List
scores. Results were similarly assessed in an un-blinded fashion
after 3months of bilateral stimulation, which showed persistent
benefit.
Welter et al. (21) reported a double-blind, randomized cross-
over study on the effect of high frequency stimulation of the
CM–Pf and/or the ventro-medial GPi which was mentioned
briefly above. Three patients with severe TS were selected for
electrode implantation. Patients were examined 1month before
surgery and 2months after surgery without stimulation. Four
stimulation conditions were randomly assigned in a cross-over
design. The conditions were (1) bilateral thalamic stimulation,
(2) bilateral GPi stimulation, (3) combined bilateral pallidal and
thalamic stimulation and (4) no stimulation. Each stimulation
condition was maintained for 2months and patients were exam-
ined monthly by blinded clinicians. The study revealed improve-
ment in the YGTSS with bilateral GPi stimulation (tic severity
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reduction ranged from 65 to 96%). Bilateral CM–Pf stimulation
also reduced tic severity, but not as dramatically (range of reduc-
tion from 30 to 64%). Interestingly, combined GPi and thalamic
stimulation did not show a further reduction in tic severity.
Motor symptoms recurred during the sham stimulation and no
neuropsychological, psychiatric or other long-term adverse effects
were observed.
Ackermans et al. (34) performed a randomized double-blind
cross-over study in six patients to assess safety of stimulation
of the Cm–Spv–Voi in the thalamus. After surgery, the patients
were randomly assigned to two groups: Group A had stimula-
tors turned on during the first 3months followed by 3months
with their stimulators off; Group B had the opposite stimulation
schedule. This was followed by 6months with the stimulators
turned on in both groups. Assessments were performed before
surgery and at 3, 6, and 12months after surgery. Tic severity
during the “on-stimulation” period was significantly lower than
during the “off-stimulation” period, with 37% improvement in
YGTSS (p= 0.046). There was a sustained effect of stimulation
1 year after surgery, with 49% improvement in YGTSS compared
to pre-operative assessments (p= 0.028). Recently, Kefalopoulou
published an RCT on pallidal DBS in TS, which indicated that
bilateral GPi (both antero-medial and posteroventral regions)
stimulation lead to improved tic severity, and was safe (seeTable 2
for summary of RCTs).
Adverse Effects
Severe surgery-related adverse effects are rare. Overall estimates of
the incidence of symptomatic intracerebral hemorrhage as a result
of DBS for all indications are about 1% (36). Infection is another
potential complication, particularly from Staphylococcus aureus in
the infraclavicular region near the battery insertion site (34). If
infection does occur, it must be identified and treated promptly,
otherwise the DBS leadsmay need to be extracted. Reported com-
plication rates are variable depending on the series. Intracranial
complications such as infection, hemorrhage, ischemic events,
and microelectrode rupture/displacement have been reported to
occur in 3.2% of subjects (37). In another series, Servello et al.
(38) reported that DBS-related infection rates were 18% in TS
compared to 3.7% overall (including DBS for PD, dystonia and
ET). They speculated that this might be due to compulsive touch-
ing of the scar which is common in patients with TS. Other
complications including subcutaneous pouch-related complica-
tions such as seroma or hematoma, wound diasthesis or infec-
tion (pouch or extension cables) have to reported in 19.3% of
subjects (37).
Changes in sexual behavior have been reported in subjects
after DBS of the CM–Spv–Voi (17). Houeto et al. (29) noted
stimulation-related weight loss after both thalamic and antero-
medial GPi stimulation. This is interesting considering PD
patients typically report weight gain after DBS (39). Reported
psychiatric symptoms include psychosis (33), depression, and
hypomania (32). Nausea, vertigo, anxiety, and social avoidance
have been reported after ventromedial GPi stimulation (21, 24,
28). Welter et al. (21) reported transient oral or arm pares-
thesias with thalamic stimulation, while pallidal stimulation
induced lethargy that lasted 3–4 days. Thalamic stimulation has
also been associated with decreased libido (21). Zhang et al.
(23) reported that patients with GPi stimulation experienced
mood symptoms including anxiety and agitation. Interestingly,
they reported that these side effects could be resolved with
detailed programing.
Nucleus accumbens stimulation can result in adverse effects
including flushing, anxiety, sweating, hypomania, agitation, and
psychosis (40). Adverse effects of DBS of the AIC to treat OCBs
and TS include euphoria, giddiness, anxiety, panic, fear, and
acutely worsening depression (41).
Future Directions
There are multiple studies ongoing investigating the use of DBS in
TS. A randomized double-blind safety/efficacy study (Clinicaltri-
als.gov, NCT02112253) is being conducted to define the optimal
location and stimulation settings for the anterior globus pallidus.
The study examines deep versus superficial electrode contact posi-
tions, compares two different amplitudes of stimulation, and aims
to recruit ten subjects. Primary outcomemeasures include YGTSS
TABLE 2 | Randomized controlled trials of DBS in TS.
Study Target Sample size Outcomes Adverse effects
Houeto
et al. (29)
CM–Pf +
bilat GPi
1 Bilateral thalamic stimulation: 65% reduction in YGTSS, 77%
improvement in RVBTS, fewer self-injurious behaviors; Bilateral
GPi stimulation: 65% reduction in YGTSS, 67% improvement in
RVCTS, fewer self-injurious behaviors, but mood and impulsivity
worse compared to bilateral thalamic stimulation
Weight loss
Ackermans
et al. (34)
CM–Spv–Voi 8 49% improvement in YGTSS, 35% improvement in RVTRS Decreased energy, subjective visual disturbance,
one small hemorrhage, persistent nystagmus
Maciunas
et al. (33)
CM–Pf 5 40–67% reduction in RVTRS, 21–70% mean reduction in vocal
tics, 43.6% reduction in YGTSS, 43% mean reduction in TSSL
Two patients had tic exacerbation, one patient
had acute psychosis
Welter
et al. (21)
CM–Pf +
Gpi
3 65–95% improvement In YGTSS with GPi only, 30–64%
improvement in YGTSS with CM–Pf only, 43–76% improvement in
YGTSS with combined stimulation
Decreased libido with thalamic stimulation;
lethargy, nausea and vertigo at high settings of
GPi stimulation
Kefalopoulou
et al. (35)
Bilat Gpi 15 Mean YGTSS scores were significantly lower at the end of the
on-stimulation period (mean improvement 12.4, or 15.3%
Two infections of DBS hardware, one episode of
hypomania. All resolved with treatment.
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scores at baseline and 3, 6, 9, 12 and 18months post-stimulation.
Two studies (Clinicaltrials.govNCT02056873 andNCT01817517)
are being conducted to evaluate the effectiveness and safety of
thalamic DBS in ten subjects. Certainly more work is needed to
understand the full potential of DBS in TS.
It is clear that further RCTs are needed to accurately determine
the effectiveness ofDBS, and as ameans of comparing one target to
another. To do so, uniform outcome measures should be selected
in the assessment of tic severity and reduction as well as quality
of life measures. Of course, clinical scores of tic severity, such
as the YGTSS, are inadequate by themselves, since they may not
account for subjective feelings of isolation, and depression which
accompany TS. It has been argued that clinician assessed video
recordings, such as the RVBTS, may introduce measurement and
error bias (42).
Summary/Key Points
Reports thus far indicate that DBS is a safe and feasible therapy,
but its efficacy for TS remains to be fully elucidated. Selecting TS
patients for DBS is challenging given the unpredictable natural
history of the disease, the varied extent to which TS patients are
hampered by their tics, the presence of co-morbid psychiatric
conditions, and the lack of consensus regarding implementation
of this procedure. Additionally, multiple suitable targets have been
identified, adding another level of complexity. Ultimately, each
TS patient should be evaluated individually to determine their
suitability for DBS. The above studies have shown that DBS for
TS is relatively safe and feasible, but large multi-center clinical
trials are needed to determine the ideal target for TS and optimal
location within a particular target.
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